This immunotoxin was achieved by conjugating/fusing the Anti-EPCAM scFv to Bouganin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to tumor cells. Once bind, the toxin enters cells by receptor-mediated endocytosis and enzymatically damages ribosomes, ultimately leading to cell death. It was designed for treatment of Head and neck cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.